Severe insulin resistance associated with subcutaneous amyloid deposition

Diabetes Research and Clinical Practice

Volumn 75, Issue 3, 2007, Pages 374-376

  Albert, Stewart G ^a   Obadiah, Joseph ^a   Parseghian, Shant A ^a   Yadira Hurley, M ^a   Mooradian, Arshag D ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Amyloid; Insulin resistance; Insulin degrading enzyme

Indexed keywords

CALCITRIOL; CAPTOPRIL; CLOPIDOGREL; DIGOXIN; EZETIMIBE PLUS SIMVASTATIN; FUROSEMIDE; INSULIN; INSULIN LISPRO; INSULINASE; ISOPHANE INSULIN;

ADULT; AMYLOIDOSIS; ARTERY DISEASE; CASE REPORT; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; EYE EXAMINATION; FOREIGN BODY GRANULOMA; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LABORATORY TEST; LETTER; MALE; PHYSICAL EXAMINATION; SKIN EXAMINATION;

AMYLOID; AMYLOIDOSIS; DIABETES MELLITUS, TYPE 1; GRANULOMA; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; SKIN; TREATMENT OUTCOME;

EID: 33846045970     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2006.07.013     Document Type: Letter

References (7)

1. Paulsen E.P., Courtney J.W., and Duckworth W.C. Insulin resistance caused by massive degradation of subcutaneous insulin. Diabetes 28 (1979) 640-645
2. Freidenberg G.R., White N., Cataland S., O'Dorisio T.M., Sotos J.F., and Santiago J.V. Diabetes responsive to intravenous but not subcutaneous insulin: effectiveness of aprotinin. N. Engl. J. Med. 305 (1981) 363-368
3. Riveline J.-P., Capeau J., Robert J.-J., and Varroud-Vial M. Extreme subcutaneous insulin resistance successfully treated by an implantable pump. Diabetes Care 24 (2001) 2155-2156
4. Gillard P., Ling Z., Lannoo M., Maes B., Maleux G., Pipeleers D., et al. β-Cell transplantation restores metabolic control and quality of life in a patient with subcutaneous insulin resistance. Diabetes Care 27 (2004) 2243-2244
5. Duckworth W.C., Bennett R.G., and Hamel F.G. Insulin degradation: progress and potential. Endocr. Rev. 19 (1998) 608-624
6. Merlini G., and Bellotti V. Molecular mechanisms of amyloidosis. N. Engl. J. Med. 349 (2003) 583-586
7. Bennett R.G., Hamel F.G., and Duckworth W.C. An insulin-degrading enzyme inhibitor decreases amylin degradation, increases amylin-induced cytotoxicity, and increases amyloid formation in insulinoma cell cultures. Diabetes 52 (2003) 2315-2320